ClinicalTrials.gg

Program

GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003

Its studies are mostly in Multiple Myeloma, led by Innovent Biologics.

Furthest: phase 3, since May 21, 20264 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics44 open or runningphase 3since May 21, 2026Oct 9, 2023Dec 31, 2026phase 2 · NCT07764861

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT06083207 · 116 planned · Australia, China
  2. Jan 8, 2026Phase 2 study in Multiple MyelomaNCT07336472 · 360 planned · United States
  3. May 21, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07623798 · 255 planned · China
  4. Aug 10, 2026Phase 2 study in Multiple MyelomaNCT07764861 · 120 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Multiple MyelomaNCT07764861
  2. Jun 30, 2027Primary completion: phase 2 study in Multiple MyelomaNCT07336472
  3. May 31, 2029Primary completion: phase 3 study in RecurrenceNCT07623798

TargetBeta

“A T-cell engager (TCE) targeting the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 38

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07764861Multiple Myeloma · China2Not yet recruitingDec 31, 2026120
NCT07623798Recurrence · China3RecruitingMay 31, 2029255
NCT07336472Multiple Myeloma · United States2RecruitingJun 30, 2027360
NCT06083207Multiple Myeloma · Australia, China2RecruitingOct 31, 2026116

How it is read

Names in the registry

  • “IBI3003”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.